Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Trial of Accelerated Adjuvant Chemotherapy With Capecitabine in Early Breast Cancer.

Next Previous
X
Search
Trial Profile

Trial of Accelerated Adjuvant Chemotherapy With Capecitabine in Early Breast Cancer.

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 02 Sep 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Capecitabine (Primary) ; Epirubicin (Primary) ; Cyclophosphamide; Cyclophosphamide; Fluorouracil; Methotrexate; Pegfilgrastim
  • Indications Early breast cancer; Male breast cancer
  • Focus Therapeutic Use
  • Acronyms TACT2

    • Most Recent Events

    • 02 Nov 2023 Results (n=1493) of QOL substudy assessing the effect of chemotherapies on psychological distress, physical symptoms, and functional domains published in the Lancet Oncology
    • 19 Mar 2014 Efficacy results on capecitabine vs CMF presented at the 9th European Breast Cancer Conference.
    • 19 Mar 2014 Accruel to date is 97% according to UK Clinical Research Network

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top